| Name | Title | Contact Details |
|---|
CODA Biotherapeutics` revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable `switch` protein. Cells modified with the `switch` can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.
Meta Systems is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A new setpoint for immunometabolism
Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.
Lynxcom Partners LLC is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.